Gilead Sciences, Inc. (GILD)
NASDAQ: GILD · Real-Time Price · USD
125.67
+0.48 (0.38%)
At close: Dec 24, 2025, 1:00 PM EST
126.00
+0.33 (0.26%)
After-hours: Dec 24, 2025, 4:42 PM EST
Gilead Sciences Revenue
Gilead Sciences had revenue of $7.77B in the quarter ending September 30, 2025, with 2.97% growth. This brings the company's revenue in the last twelve months to $29.09B, up 2.78% year-over-year. In the year 2024, Gilead Sciences had annual revenue of $28.75B with 6.04% growth.
Revenue (ttm)
$29.09B
Revenue Growth
+2.78%
P/S Ratio
5.38
Revenue / Employee
$1,652,670
Employees
17,600
Market Cap
155.92B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 28.75B | 1.64B | 6.04% |
| Dec 31, 2023 | 27.12B | -165.00M | -0.60% |
| Dec 31, 2022 | 27.28B | -24.00M | -0.09% |
| Dec 31, 2021 | 27.31B | 2.62B | 10.60% |
| Dec 31, 2020 | 24.69B | 2.24B | 9.98% |
| Dec 31, 2019 | 22.45B | 322.00M | 1.46% |
| Dec 31, 2018 | 22.13B | -3.98B | -15.24% |
| Dec 31, 2017 | 26.11B | -4.28B | -14.09% |
| Dec 31, 2016 | 30.39B | -2.25B | -6.89% |
| Dec 31, 2015 | 32.64B | 7.75B | 31.13% |
| Dec 31, 2014 | 24.89B | 13.69B | 122.19% |
| Dec 31, 2013 | 11.20B | 1.50B | 15.46% |
| Dec 31, 2012 | 9.70B | 1.32B | 15.70% |
| Dec 31, 2011 | 8.39B | 435.97M | 5.48% |
| Dec 31, 2010 | 7.95B | 938.04M | 13.38% |
| Dec 31, 2009 | 7.01B | 1.68B | 31.40% |
| Dec 31, 2008 | 5.34B | 1.11B | 26.14% |
| Dec 31, 2007 | 4.23B | 1.20B | 39.78% |
| Dec 31, 2006 | 3.03B | 997.74M | 49.19% |
| Dec 31, 2005 | 2.03B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
GILD News
- 3 days ago - Gilead Sciences to Present at Upcoming Investor Conference - Business Wire
- 3 days ago - Gilead Sciences Exercises Option to License Assembly Biosciences' Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes - Business Wire
- 6 days ago - Nine pharmaceutical companies including Bristol-Myers Squibb, GSK and Merck agreed to lower the prices that certain federal government programs and patients pay - WSJ
- 6 days ago - Trump strikes deal with US drugmakers to cut Medicaid medicine costs - The Guardian
- 6 days ago - Nine of the largest pharma companies ink deals with Trump to lower drug prices - CNBC
- 6 days ago - Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans - Business Wire
- 6 days ago - Trump to announce new drug-pricing deals later today - Market Watch
- 7 days ago - Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance - Business Wire